이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Kexing Biopharm 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Yanqing Zhao

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	5yrs
CEO 소유권	0.04%
경영진 평균 재임 기간	5yrs
이사회 평균 재임 기간	5yrs

최근 관리 업데이트

Recent updates

Kexing Biopharm Co., Ltd.'s (SHSE:688136) Share Price Boosted 36% But Its Business Prospects Need A Lift Too

May 21

Shandong Kexing Bioproducts Co,.Ltd (SHSE:688136) Held Back By Insufficient Growth Even After Shares Climb 25%

Mar 08

CEO

Yanqing Zhao (42 yo)

5yrs

테뉴어

Mr. Yanqing Zhao is MD & Director of Shandong Kexing Bioproducts Co, Ltd from July 29, 2019.

리더십 팀

이름	위치	테뉴어	보상	소유권
Xiaoqin Wang	CFO & Secretary to the Board of Directors	5yrs	CN¥738.60k	0.020% CN¥ 634.3k
Suofu Qin	Deputy General Manager	no data	CN¥1.28m	0.023% CN¥ 729.9k
Ke Shao	Deputy General Manager	no data	CN¥1.44m	0.041% CN¥ 1.3m
Yanqing Zhao	MD & Director	5yrs	데이터 없음	0.038% CN¥ 1.2m
Hongjie Ma	Deputy General Manager	no data	데이터 없음	0.018% CN¥ 562.7k
Ning Cui	Deputy GM & Director	5yrs	데이터 없음	0.016% CN¥ 520.3k

5.0yrs

평균 재임 기간

50yo

평균 연령

경험이 풍부한 관리: 688136 의 관리팀은 노련하고 경험 (평균 재직 기간 5 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Yanqing Zhao	MD & Director	5yrs	데이터 없음	0.038% CN¥ 1.2m
Ning Cui	Deputy GM & Director	5yrs	데이터 없음	0.016% CN¥ 520.3k
An Tang	Independent Director	5yrs	CN¥180.00k	데이터 없음
Xueqin Deng	Chairman of the Board	5yrs	데이터 없음	67.48% CN¥ 2.2b
Jianhong Tao	Independent Director	5yrs	CN¥180.00k	데이터 없음
Die Li	Employee Representative Supervisor	2yrs	데이터 없음	데이터 없음

5.0yrs

평균 재임 기간

52yo

평균 연령

경험이 풍부한 이사회: 688136 의 이사회는 경험(평균 재직 기간 4.9 년)으로 간주됩니다.

Kexing Biopharm 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Kexing Biopharm Co., Ltd., Annual General Meeting, May 24, 2024

Kexing Biopharm Co., Ltd., Annual General Meeting, May 24, 2024

Less than half of directors are independent

Insufficient new directors

Recent updates

Kexing Biopharm Co., Ltd. to Report First Half, 2024 Results on Aug 24, 2024

Kexing Biopharm Co., Ltd. Announces Its Subsidiary Shenzhen Kexing Pharmaceutical Co., Ltd., Obtains Clinical Trial Approval for its Self-Developed Class I Innovative Drug--Long-Acting Growth Hormone

Kexing Biopharm Co., Ltd.'s (SHSE:688136) Share Price Boosted 36% But Its Business Prospects Need A Lift Too

Kexing Biopharm Co., Ltd., Annual General Meeting, May 24, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Kexing Biopharm Co., Ltd., Annual General Meeting, May 24, 2024

Shenzhen Kexing Pharmaceutical Co., Ltd. Announces Enrollment of Subjects in Phase III Clinical Trial for Inhaled Aerosol Drug in Children by Kexing Biopharm

Shandong Kexing Bioproducts Co,.Ltd to Report Q1, 2024 Results on Apr 27, 2024

Shandong Kexing Bioproducts Co,.Ltd (SHSE:688136) Held Back By Insufficient Growth Even After Shares Climb 25%

Less than half of directors are independent

Shandong Kexing Bioproducts Co,.Ltd (SHSE:688136) announces an Equity Buyback for CNY 60 million worth of its shares.

New minor risk - Share price stability

Third quarter 2023 earnings released: CN¥0.033 loss per share (vs CN¥0.23 loss in 3Q 2022)

Second quarter 2023 earnings released: CN¥0.22 loss per share (vs CN¥0.13 loss in 2Q 2022)

Shandong Kexing Bioproducts Co,.Ltd announced that it expects to receive CNY 571.6 million in funding

Shandong Kexing Bioproducts Co,.Ltd to Report First Half, 2023 Results on Aug 26, 2023

First quarter 2023 earnings released: CN¥0.04 loss per share (vs CN¥0.15 profit in 1Q 2022)

Full year 2022 earnings released: CN¥0.45 loss per share (vs CN¥0.49 profit in FY 2021)

Insufficient new directors

Third quarter 2022 earnings released: CN¥8.24 loss per share (vs CN¥0.072 profit in 3Q 2021)

Second quarter 2022 earnings released: CN¥0.068 loss per share (vs CN¥0.075 profit in 2Q 2021)

First quarter 2022 earnings released: EPS: CN¥0.15 (vs CN¥0.23 in 1Q 2021)

Full year 2021 earnings released: EPS: CN¥0.49 (vs CN¥0.93 in FY 2020)

Investor sentiment improved over the past week

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.072 (vs CN¥0.16 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.075 (vs CN¥0.16 in 2Q 2020)

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥0.93 (vs CN¥1.07 in FY 2019)

Shan Dong Kexing Bioproducts Co., Ltd has completed an IPO in the amount of CNY 1.109249 billion.

CEO

테뉴어

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령